Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928943 | 0.87 | — | — | |
| SCHEMBL4966983 | 0.87 | — | — | |
| SCHEMBL6726808 | 0.86 | PIK3CD (0.32) | PIK3CDMEN1KMT2A | |
| Trifosmin SCHEMBL291309 | 0.81 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL20267488 | 0.80 | PIK3CD (0.31) | PIK3CDMEN1KMT2A | |
| SCHEMBL14214651 | 0.80 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL20267861 | 0.78 | PIK3CD (0.30) | PIK3CDMEN1KMT2A | |
| Trifosmin SCHEMBL8406572 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7142674 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13925694 | 0.76 | PIK3CD (0.37) | PIK3CDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307239-B1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2008-10-08 | — | — | EP | claimed |
| EP-1307239-B1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080124273-A1 | Novel cationic metal complex radiopharmaceuticals | PURDUE RESEARCH FOUNDATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124273-A1 | Novel cationic metal complex radiopharmaceuticals | PURDUE RESEARCH FOUNDATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124273-A1 | Novel cationic metal complex radiopharmaceuticals | SLC39A14, CLTC, TMEM165 | PIK3CD 2690/4885ALDH1A1 4775/4885MEN1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.